The manufacturing of medicinal products is for us not only a matter of implementing a certain technological process, but a human mission based on high standards of quality, safety and efficacy of medications
SOPHARMA AD hereby informs that on 8 August 2016 the Company bought 450 own shares representing 0.00033% of the share capital of the Company, at a total value of 1242.00 BGN on the Bulgarian Stock Exchange, the average price per share was 2.76 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 468 688, representing 4.06% of the share capital of the Company.
For the first seven months of this year, revenues from sales decreased by 3% compared to the same period of 2015, including same level of domestic sales and a 4% decrease of export sales.
The good results in July led to reduced decrease of revenues for the period which was mainly due to the instability of the Russian market.
SOPHARMA AD hereby informs that from 2 August 2016 up to and including 4 August 2016 the Company bought 4 464 own shares representing 0.0033% of the share capital of the Company, at a total value of 12 410.83 BGN on the Bulgarian Stock Exchange, the average price per share was 2.78 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 468 238, representing 4.06% of the share capital of the Company.